Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EBMT 2019 | The importance of QoL in guiding myeloma therapy

Karthik Ramasamy • 24 Mar 2019
EBMT 2019
General Multiple Myeloma

Karthik Ramasamy, PhD, from Oxford University Hospitals, Oxford, UK, emphasizes the importance of factoring in the quality of life (QoL) of patients to guide therapy. Dr Ramasamy was speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

More from Karthik Ramasamy

Reasons for treatment discontinuation in multiple myeloma: insights from the PREAMBLE registry 1:29
Reasons for treatment discontinuation in multiple myeloma: insights from the PREAMBLE registry
Karthik Ramasamy • 7 Dec 2025
Optimizing the dose of belamaf in transplant-ineligible NDMM: insights from the DREAMM-9 trial 1:55
Optimizing the dose of belamaf in transplant-ineligible NDMM: insights from the DREAMM-9 trial
Karthik Ramasamy • 15 Sep 2025
Updates on current research exploring treatment strategies for high-risk smoldering myeloma 2:14
Updates on current research exploring treatment strategies for high-risk smoldering myeloma
Karthik Ramasamy • 15 Sep 2025
The psychological impact of being diagnosed with MGUS: insights from the SECURE study 2:15
The psychological impact of being diagnosed with MGUS: insights from the SECURE study
Karthik Ramasamy • 15 Sep 2025

Related Videos

Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
Prolonged elranatamab treatment interruption in R/R myeloma: MagnetisMM-3 retrospective analysis 2:35
Prolonged elranatamab treatment interruption in R/R myeloma: MagnetisMM-3 retrospective analysis
Alexander Lesokhin • 8 Dec 2025
Integrated approaches to improve prognosis prediction in multiple myeloma 2:32
Integrated approaches to improve prognosis prediction in multiple myeloma
Claudio Cerchione • 6 Dec 2025
Using artificial intelligence to accelerate patient eligibility screening in clinical trials 1:52
Using artificial intelligence to accelerate patient eligibility screening in clinical trials
Aaron Gerds • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals